𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Reply: Cerebrospinal fluid Aβ42 levels in multiple system atrophy

✍ Scribed by Bjorn Holmberg

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
57 KB
Volume
19
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The letter to which this article refers can be found online: Mov Disord 2004;19(2):238–240.

📜 SIMILAR VOLUMES

Cerebrospinal fluid hypocretin-1 levels
Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy
✍ Jose Enrique Martinez-Rodriguez; Klaus Seppi; Adriana Cardozo; Alex Iranzo; Mich 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

## Abstract Hypocretin (orexin) cerebrospinal fluid (CSF) levels have been previously found normal or decreased in Dementia with Lewy bodies and Parkinson disease, two synucleinopathies commonly associated with excessive daytime sleepiness (EDS). We evaluated CSF hypocretin‐1 levels in 15 patients

Cerebrospinal fluid Aβ42 is reduced in m
Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy
✍ Björn Holmberg; Bo Johnels; Kaj Blennow; Lars Rosengren 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

## Abstract The 42‐amino–acid isoform of β‐amyloid Aβ42 in the cerebrospinal fluid (CSF) has recently been proposed as a biochemical marker for Alzheimer's disease (AD) and subcortical white‐matter dementia (SWD). In both of these conditions, concentration of CSF‐Aβ42 is reduced. We quantified CSF‐

Decreased cerebrospinal fluid Aβ42 corre
Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly
✍ Anne M. Fagan; Denise Head; Aarti R. Shah; Daniel Marcus; Mark Mintun; John C. M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 1 views

## Abstract ## Objective For therapies for Alzheimer's disease (AD) to have the greatest impact, it will likely be necessary to treat individuals in the “preclinical” (presymptomatic) stage. Fluid and neuroimaging measures are being explored as possible biomarkers of AD pathology that could aid in

Increased brain atrophy rates in cogniti
Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42
✍ Jonathan M. Schott; Jonathan W. Bartlett; Nick C. Fox; Josephine Barnes; for the 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 234 KB 👁 2 views

Objective: To identify cognitively normal individuals at risk of Alzheimer disease (AD) based on cerebrospinal fluid (CSF) Ab1-42, and to determine rates of cerebral atrophy. Methods: Control subjects from the Alzheimer's Disease Neuroimaging Initiative with CSF and serial magnetic resonance imaging